NCT06248606

Adagrasib + SRS for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

Phase II Study of Adagrasib + Stereotactic Radiosurgery (SRS) for Patients With Metastatic KRAS G12C-mutated NSCLC With Untreated Brain Metastases

• Status: Recruiting
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 30 (estimated)
• Sponsor: Ryan Gentzler, MD · Academic / Other
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

This is a single arm phase 2 trial is to evaluate the efficacy of SRS plus adagrasib for the treatment of brain metastases for patients with KRAS G12C-mutated non-small cell lung cancer (NSCLC). A total of 30 patients will be enrolled on this study.

Conditions

• Non Small Cell Lung Cancer
• NSCLC
• KRAS G12C

Interventions

Type	Name	Description
DRUG	Adagrasib	Adagrasib 600mg orally
RADIATION	Stereotactic Radiosurgery	Delivered as per standard of care

Timeline

• Start date: 2024-08-06
• Primary completion: 2027-02-25
• Completion: 2028-02-25
• First posted: 2024-02-08
• Last updated: 2026-04-08

Locations

3 sites across 1 country: United States

Regulatory

• FDA-regulated drug study